ArticleThoracic cancer2025

Planning Target Volume and Nodal Status Predict Clinical Outcomes After Chemoradiation and Durvalumab in Stage III Non-Small Cell Lung Cancer.

Ori Aslan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.